S2446 Association of Fib-4 Score and Body Mass Index With Cirrhosis in a Contemporary MASLD Cohort

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading cause of chronic liver disease globally, with rates of advanced fibrosis and cirrhosis rising rapidly. While noninvasive scores such as Fib-4 are widely used to estimate fibrosis risk, and obesity is a recognized risk factor for MASLD progression, the quantitative relationship between BMI and cirrhosis remains incompletely defined. We aimed to evaluate the independent and combined associations of Fib-4 and BMI with cirrhosis in a MASLD cohort, and to determine whether the risk of cirrhosis rises progressively with increasing BMI once obesity is established. Methods: We conducted a retrospective cross-sectional study of 80 adults with MASLD followed at a veteran's affair hospital. Multiple clinical and laboratory data were abstracted from the EMR. Cirrhosis was defined by provider diagnosis or evidence of decompensated liver disease. Patients were categorized into BMI quartiles and standard obesity classes. Group comparisons were made using Mann-Whitney U test and Fisher’s exact test as appropriate. Multivariable logistic regression evaluated Fib-4 and BMI as independent predictors of cirrhosis, and a quadratic term for BMI was used to assess for dose-response versus plateau effects. Results: Of 80 patients, 6 (7.4%) had cirrhosis. Median Fib-4 was significantly higher in cirrhosis patients (4.00 [IQR: 3.16–4.97] vs 1.20 [IQR: 0.87–1.82], P = 0.021), and median BMI was also higher (36.7 [IQR: 33.6–42.1] vs 31.2 [IQR: 27.5–33.2], P = 0.009). The prevalence of cirrhosis increased stepwise across BMI quartiles: 0% in Q1 (BMI ≤28.3), 5% in Q2 (28.3–30.7), 8% in Q3 (30.8–34.8), and 18% in Q4 (BMI ≥34.9). Cirrhosis rates by BMI category were 0% (normal/underweight), 5% (overweight), 8% (obese I), 11% (obese II), and 20% (obese III). Logistic regression confirmed both Fib-4 (OR per unit: 2.17, 95% CI 1.14–4.13, P = 0.018) and BMI (OR per unit: 1.19, 95% CI 1.05–1.37, P = 0.007) as independent predictors of cirrhosis. Conclusion: In this contemporary MASLD cohort, both Fib-4 score and body mass index were independently and additively associated with cirrhosis. The risk of cirrhosis increased progressively with rising BMI rather than plateauing once obesity was established. These findings underscore the importance of aggressive risk factor modification and routine risk stratification in patients with elevated BMI. Further prospective studies are warranted to confirm these observations and inform optimal surveillance strategies for high-risk populations.

Authors

Publication Details

Journal
The American Journal of Gastroenterology
Published
2025-10-01
DOI
https://doi.org/10.14309/01.ajg.0001137244.68532.20
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

S2446 Association of Fib-4 Score and Body Mass Index With Cirrhosis in a Contemporary MASLD Cohort

Kartick Patra, Pallavi Kawatra, Jacky Reny, Louis E. Fisher et al.
The American Journal of Gastroenterology
Liver Disease Diagnosis and Treatment
article

S2446 Association of Fib-4 Score and Body Mass Index With Cirrhosis in a Contemporary MASLD Cohort

Kartick Patra, Pallavi Kawatra, Jacky Reny, Louis E. Fisher, Jordan Barnett-Kradjian
article en

Abstract

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading cause of chronic liver disease globally, with rates of advanced fibrosis and cirrhosis rising rapidly. While noninvasive scores such as Fib-4 are widely used to estimate fibrosis risk, and obesity is a recognized risk factor for MASLD progression, the quantitative relationship between BMI and cirrhosis remains incompletely defined. We aimed to evaluate the independent and combined associations of Fib-4 and BMI with cirrhosis in a MASLD cohort, and to determine whether the risk of cirrhosis rises progressively with increasing BMI once obesity is established. Methods: We conducted a retrospective cross-sectional study of 80 adults with MASLD followed at a veteran's affair hospital. Multiple clinical and laboratory data were abstracted from the EMR. Cirrhosis was defined by provider diagnosis or evidence of decompensated liver disease. Patients were categorized into BMI quartiles and standard obesity classes. Group comparisons were made using Mann-Whitney U test and Fisher’s exact test as appropriate. Multivariable logistic regression evaluated Fib-4 and BMI as independent predictors of cirrhosis, and a quadratic term for BMI was used to assess for dose-response versus plateau effects. Results: Of 80 patients, 6 (7.4%) had cirrhosis. Median Fib-4 was significantly higher in cirrhosis patients (4.00 [IQR: 3.16–4.97] vs 1.20 [IQR: 0.87–1.82], P = 0.021), and median BMI was also higher (36.7 [IQR: 33.6–42.1] vs 31.2 [IQR: 27.5–33.2], P = 0.009). The prevalence of cirrhosis increased stepwise across BMI quartiles: 0% in Q1 (BMI ≤28.3), 5% in Q2 (28.3–30.7), 8% in Q3 (30.8–34.8), and 18% in Q4 (BMI ≥34.9). Cirrhosis rates by BMI category were 0% (normal/underweight), 5% (overweight), 8% (obese I), 11% (obese II), and 20% (obese III). Logistic regression confirmed both Fib-4 (OR per unit: 2.17, 95% CI 1.14–4.13, P = 0.018) and BMI (OR per unit: 1.19, 95% CI 1.05–1.37, P = 0.007) as independent predictors of cirrhosis. Conclusion: In this contemporary MASLD cohort, both Fib-4 score and body mass index were independently and additively associated with cirrhosis. The risk of cirrhosis increased progressively with rising BMI rather than plateauing once obesity was established. These findings underscore the importance of aggressive risk factor modification and routine risk stratification in patients with elevated BMI. Further prospective studies are warranted to confirm these observations and inform optimal surveillance strategies for high-risk populations.

The American Journal of GastroenterologyVol. 120(10S2)
Openalex Percentile: Top 49%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.